سعر فليبانواكت 100مجم 28 قرص 2023

Flibanserin 100 mg film-coated tablets, 28 tablets (4 strips x 7).

• Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, not due to a co-existing condition, relationship problems or medication effects.Population: Premenopausal women (US label also covers naturally postmenopausal women younger than 65)DailyMed (U.S. NLM)

• Most common (>=2%): dizziness, somnolence, nausea, fatigue, insomnia and dry mouth.International label, same formulation · DailyMed (U.S. NLM)

• Concomitant use of moderate or strong CYP3A4 inhibitors.International label, same formulation · DailyMed (U.S. NLM)
• Hepatic impairment.International label, same formulation · DailyMed (U.S. NLM)
• Known hypersensitivity to flibanserin or any component (anaphylaxis, angioedema reported).International label, same formulation · DailyMed (U.S. NLM)

• Boxed warning: severe hypotension and syncope when taken too close to alcohol; follow the alcohol timing rules.International label, same formulation · DailyMed (U.S. NLM)
• Hypotension and syncope can occur even without alcohol, and with moderate/strong CYP3A4 inhibitors.International label, same formulation · DailyMed (U.S. NLM)
• CNS depression (somnolence, sedation); avoid driving or hazardous activities for at least 6 hours after a dose and until the effect is known.International label, same formulation · DailyMed (U.S. NLM)

• Moderate or strong CYP3A4 inhibitorsContraindicated: increased flibanserin exposure, severe hypotension and syncope. Start the inhibitor at least 2 days after the last flibanserin dose; start flibanserin at least 2 weeks after the last inhibitor dose.DailyMed (U.S. NLM)
• AlcoholIncreased risk of severe hypotension and syncope; follow dosing-time rules.DailyMed (U.S. NLM)
• CNS depressants (e.g. opioids, benzodiazepines, hypnotics)May increase CNS depression.DailyMed (U.S. NLM)

• No adequate human data on use in pregnancy; discontinue if pregnancy occurs (indication does not apply in pregnancy).International label, same formulation · DailyMed (U.S. NLM)
• Breastfeeding is not recommended during treatment (potential serious adverse reactions such as sedation in the infant).International label, same formulation · DailyMed (U.S. NLM)

• Flibanserin: Mechanism in HSDD is unknown; in vitro it has high affinity as a 5-HT1A agonist and 5-HT2A antagonist (US ADDYI label).